RMC-0331

CAS No. 2488788-52-7

RMC-0331( —— )

Catalog No. M35014 CAS No. 2488788-52-7

RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor with potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 interactions.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 225 Get Quote
5MG 353 Get Quote
10MG 630 Get Quote
25MG 1260 Get Quote
50MG 1950 Get Quote
100MG 2844 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RMC-0331
  • Note
    Research use only, not for human use.
  • Brief Description
    RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor with potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 interactions.
  • Description
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2488788-52-7
  • Formula Weight
    499.91
  • Molecular Formula
    C22H25ClF3N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (250.05 mM; Ultrasonic )
  • SMILES
    COC1(CCOCC1)C(=O)N1Cc2nc(Cl)nc(N[C@H](C)c3cc(N)cc(c3)C(F)(F)F)c2C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Andreas Buckl, et al. Discovery of a Potent, Selective and Orally Bioavailable SOS1 Inhibitor, RMC-0331 (RM-023), an in vivo Tool Compound that Blocks RAS Activation via Disruption of the RAS-SOS1 Interaction.
molnova catalog
related products
  • SU6656

    SU 6656 is a selective inhibitor of Src family kinases, with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Sorafenib tosylate

    A potent, orally available Raf inhibitor with IC50 of 6, 22, and 38 nM for Raf-1, wt Braf, and BRaf V599E, respectively.

  • B-Raf IN 15

    B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used in the study of melanoma and cancer, and can be optimized for use as a more effective BRA F inhibitor.